Status: Recruiting
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) for the treatment of platinum sensitive recurrent ovarian cancer. Participants will receive pembrolizumab and lenvatinib.
Participants needed: 24
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: Sheba Medical CenterUpdated: Jun 8, 2023Locations: 1
Eligibility criteria
Female participants who are at least 18 years of age on the day of signing infor... [+6]
A WOCBP who has a positive urine pregnancy test [+31]